Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2019 | Impact of specific mutations on PARP inhibition in prostate cancer

Emmanuel Antonarakis • 6 Mar 2019
GU Cancers 2019
Genitourinary Cancer Prostate Cancer Rucaparib

Emmanuel Antonarakis, MBBCh, of Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, speaks at the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA. He dicusses a recent publication by his group on the impact of certain genes mutations on PARP inhibition in prostate cancer, including ATM, CDK12 and BRCA1/2.

More from Emmanuel Antonarakis

3:56
PARP inhibitors: activity in BRCA1 versus BRCA2 altered mCRPC
Emmanuel Antonarakis • 12 Feb 2021
2:58
Characterization of PSA responses to bipolar androgen therapy in mCRPC
Emmanuel Antonarakis • 12 Feb 2021
1:46
Genomic and clinical features of SPOP mutations in prostate cancer
Emmanuel Antonarakis • 12 Feb 2021
3:18
KEYNOTE-199: an update on pembrolizumab for mCRPC
Emmanuel Antonarakis • 13 Feb 2020

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals